Recomgen Biotech
Guangzhou
About Recomgen Biotech
Recomgen Biotech is an innovative biopharmaceutical company that focuses on large-scale serum-free continuous animal cell culture technology and the R&D of new biological drugs. Recomgen Biotech is working on developing rhTNK-tPA, a generation-specific thrombolytic drug that can be injected intravenously in a single dose, making it convenient for emergency treatment and out-of-hospital thrombolysis as needed. It improves the treatment rate, clinical benefit, and personal and societal medical burdens in patients with acute myocardial infarction who received thrombolytic therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Total funding: $9.2M
- Funding stage: M&A
- Last round: Series C (Oct 2019)
- Website: recomgenbio.com
- Phone: 86-2082209991
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Sales
Social Profiles
Canonical: https://fsome.com/organization/recomgen-biotech-76017 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.